vs
渤健（BIIB）与Chewy, Inc.（CHWY）财务数据对比。点击上方公司名可切换其他公司
Chewy, Inc.的季度营收约是渤健的1.4倍（$3.1B vs $2.3B），Chewy, Inc.净利率更高（1.9% vs -2.1%，领先4.0%），Chewy, Inc.同比增速更快（8.3% vs -7.1%），渤健自由现金流更多（$468.0M vs $175.8M），过去两年Chewy, Inc.的营收复合增速更高（4.6% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Chewy Inc.是总部位于美国佛罗里达州普兰泰申的宠物用品线上零售商，主营宠物食品及各类宠物相关产品，2019年于纽约证券交易所挂牌上市，股票代码CHWY，是北美知名的宠物电商平台，为宠物主提供丰富可靠的一站式宠物消费选购服务。
BIIB vs CHWY — 直观对比
营收规模更大
CHWY
是对方的1.4倍
$2.3B
营收增速更快
CHWY
高出15.4%
-7.1%
净利率更高
CHWY
高出4.0%
-2.1%
自由现金流更多
BIIB
多$292.2M
$175.8M
两年增速更快
CHWY
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $3.1B |
| 净利润 | $-48.9M | $59.2M |
| 毛利率 | 78.3% | 29.8% |
| 营业利润率 | -2.5% | 2.1% |
| 净利率 | -2.1% | 1.9% |
| 营收同比 | -7.1% | 8.3% |
| 净利润同比 | -118.3% | 1405.6% |
| 每股收益（稀释后） | $-0.35 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBCHWY
| Q4 25 | $2.3B | $3.1B | ||
| Q3 25 | $2.5B | $3.1B | ||
| Q2 25 | $2.6B | $3.1B | ||
| Q1 25 | $2.4B | $3.2B | ||
| Q4 24 | $2.5B | $2.9B | ||
| Q3 24 | $2.5B | $2.9B | ||
| Q2 24 | $2.5B | $2.9B | ||
| Q1 24 | $2.3B | $2.8B |
净利润BIIBCHWY
| Q4 25 | $-48.9M | $59.2M | ||
| Q3 25 | $466.5M | $62.0M | ||
| Q2 25 | $634.8M | $62.4M | ||
| Q1 25 | $240.5M | $22.8M | ||
| Q4 24 | $266.7M | $3.9M | ||
| Q3 24 | $388.5M | $299.1M | ||
| Q2 24 | $583.6M | $66.9M | ||
| Q1 24 | $393.4M | $34.3M |
毛利率BIIBCHWY
| Q4 25 | 78.3% | 29.8% | ||
| Q3 25 | 73.4% | 30.4% | ||
| Q2 25 | 77.1% | 29.6% | ||
| Q1 25 | 74.1% | 28.5% | ||
| Q4 24 | 76.2% | 29.3% | ||
| Q3 24 | 74.1% | 29.5% | ||
| Q2 24 | 77.8% | 29.7% | ||
| Q1 24 | 76.3% | 28.2% |
营业利润率BIIBCHWY
| Q4 25 | -2.5% | 2.1% | ||
| Q3 25 | 22.0% | 2.2% | ||
| Q2 25 | 28.1% | 2.5% | ||
| Q1 25 | 12.8% | -0.3% | ||
| Q4 24 | 11.9% | 0.9% | ||
| Q3 24 | 18.3% | 1.1% | ||
| Q2 24 | 28.3% | 2.2% | ||
| Q1 24 | 20.3% | -0.7% |
净利率BIIBCHWY
| Q4 25 | -2.1% | 1.9% | ||
| Q3 25 | 18.4% | 2.0% | ||
| Q2 25 | 24.0% | 2.0% | ||
| Q1 25 | 9.9% | 0.7% | ||
| Q4 24 | 10.9% | 0.1% | ||
| Q3 24 | 15.8% | 10.5% | ||
| Q2 24 | 23.7% | 2.3% | ||
| Q1 24 | 17.2% | 1.2% |
每股收益（稀释后）BIIBCHWY
| Q4 25 | $-0.35 | $0.14 | ||
| Q3 25 | $3.17 | $0.14 | ||
| Q2 25 | $4.33 | $0.15 | ||
| Q1 25 | $1.64 | $0.07 | ||
| Q4 24 | $1.82 | $0.01 | ||
| Q3 24 | $2.66 | $0.68 | ||
| Q2 24 | $4.00 | $0.15 | ||
| Q1 24 | $2.70 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $701.5M |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $469.4M |
| 总资产 | $29.4B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBCHWY
| Q4 25 | — | $701.5M | ||
| Q3 25 | — | $591.8M | ||
| Q2 25 | — | $616.4M | ||
| Q1 25 | — | $596.7M | ||
| Q4 24 | — | $507.5M | ||
| Q3 24 | — | $695.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
总债务BIIBCHWY
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBCHWY
| Q4 25 | $18.3B | $469.4M | ||
| Q3 25 | $18.2B | $389.9M | ||
| Q2 25 | $17.6B | $375.6M | ||
| Q1 25 | $17.0B | $261.5M | ||
| Q4 24 | $16.7B | $223.4M | ||
| Q3 24 | $16.4B | $486.7M | ||
| Q2 24 | $15.9B | $642.9M | ||
| Q1 24 | $15.2B | $510.2M |
总资产BIIBCHWY
| Q4 25 | $29.4B | $3.3B | ||
| Q3 25 | $29.2B | $3.1B | ||
| Q2 25 | $28.3B | $3.1B | ||
| Q1 25 | $28.0B | $3.0B | ||
| Q4 24 | $28.0B | $3.0B | ||
| Q3 24 | $28.3B | $3.1B | ||
| Q2 24 | $26.8B | $3.2B | ||
| Q1 24 | $26.6B | $3.2B |
负债/权益比BIIBCHWY
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $207.9M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $175.8M |
| 自由现金流率自由现金流/营收 | 20.5% | 5.6% |
| 资本支出强度资本支出/营收 | 1.9% | 1.0% |
| 现金转化率经营现金流/净利润 | — | 3.51× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $487.0M |
8季度趋势，按日历期对齐
经营现金流BIIBCHWY
| Q4 25 | $511.9M | $207.9M | ||
| Q3 25 | $1.3B | $133.9M | ||
| Q2 25 | $160.9M | $86.4M | ||
| Q1 25 | $259.3M | $207.5M | ||
| Q4 24 | $760.9M | $183.5M | ||
| Q3 24 | $935.6M | $123.4M | ||
| Q2 24 | $625.8M | $81.9M | ||
| Q1 24 | $553.2M | $98.9M |
自由现金流BIIBCHWY
| Q4 25 | $468.0M | $175.8M | ||
| Q3 25 | $1.2B | $105.9M | ||
| Q2 25 | $134.3M | $48.7M | ||
| Q1 25 | $222.2M | $156.6M | ||
| Q4 24 | $721.6M | $151.8M | ||
| Q3 24 | $900.6M | $91.5M | ||
| Q2 24 | $592.3M | $52.6M | ||
| Q1 24 | $507.3M | $66.5M |
自由现金流率BIIBCHWY
| Q4 25 | 20.5% | 5.6% | ||
| Q3 25 | 48.4% | 3.4% | ||
| Q2 25 | 5.1% | 1.6% | ||
| Q1 25 | 9.1% | 4.8% | ||
| Q4 24 | 29.4% | 5.3% | ||
| Q3 24 | 36.5% | 3.2% | ||
| Q2 24 | 24.0% | 1.8% | ||
| Q1 24 | 22.1% | 2.3% |
资本支出强度BIIBCHWY
| Q4 25 | 1.9% | 1.0% | ||
| Q3 25 | 1.8% | 0.9% | ||
| Q2 25 | 1.0% | 1.2% | ||
| Q1 25 | 1.5% | 1.6% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 1.4% | 1.1% | ||
| Q2 24 | 1.4% | 1.0% | ||
| Q1 24 | 2.0% | 1.1% |
现金转化率BIIBCHWY
| Q4 25 | — | 3.51× | ||
| Q3 25 | 2.73× | 2.16× | ||
| Q2 25 | 0.25× | 1.38× | ||
| Q1 25 | 1.08× | 9.10× | ||
| Q4 24 | 2.85× | 46.66× | ||
| Q3 24 | 2.41× | 0.41× | ||
| Q2 24 | 1.07× | 1.22× | ||
| Q1 24 | 1.41× | 2.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
CHWY
暂无分部数据
